FBRX Forte Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FBRX

Price (delayed)

$0.739

Market cap

$26.9M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1

Enterprise value

-$10.23M

Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and ...

Highlights
FBRX's quick ratio has surged by 64% since the previous quarter but it is down by 22% year-on-year
FBRX's EPS is down by 25% YoY but it is up by 19% QoQ
The net income has plunged by 127% YoY and by 3.3% from the previous quarter
The equity has contracted by 13% from the previous quarter and by 9% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fortebiorx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of FBRX
Market
Shares outstanding
36.39M
Market cap
$26.9M
Enterprise value
-$10.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$31.48M
EBITDA
-$31.47M
Free cash flow
-$28.79M
Per share
EPS
-$1
Free cash flow per share
-$0.91
Book value per share
$0.97
Revenue per share
$0
TBVPS
$1.23
Balance sheet
Total assets
$38.98M
Total liabilities
$3.67M
Debt
$0
Equity
$35.31M
Working capital
$34.66M
Liquidity
Debt to equity
0
Current ratio
10.45
Quick ratio
10.13
Net debt/EBITDA
1.18
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-81.4%
Return on equity
-94.3%
Return on invested capital
N/A
Return on capital employed
-89.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FBRX stock price

How has the Forte Biosciences stock price performed over time
Intraday
4.08%
1 week
-5.26%
1 month
4.08%
1 year
-29.62%
YTD
-10.06%
QTD
6.15%

Financial performance

How have Forte Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$32.49M
Net income
-$31.48M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 134% YoY and by 4.6% from the previous quarter
The net income has plunged by 127% YoY and by 3.3% from the previous quarter

Growth

What is Forte Biosciences's growth rate over time

Valuation

What is Forte Biosciences stock price valuation
P/E
N/A
P/B
0.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
FBRX's EPS is down by 25% YoY but it is up by 19% QoQ
The price to book (P/B) is 83% lower than the 5-year quarterly average of 4.4 but 4.3% higher than the last 4 quarters average of 0.7
The equity has contracted by 13% from the previous quarter and by 9% YoY

Efficiency

How efficient is Forte Biosciences business performance
FBRX's return on equity has dropped by 172% year-on-year and by 6% since the previous quarter
The company's return on assets has shrunk by 147% YoY and by 5% QoQ

Dividends

What is FBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FBRX.

Financial health

How did Forte Biosciences financials performed over time
The current ratio has surged by 66% since the previous quarter but it has declined by 20% year-on-year
FBRX's quick ratio has surged by 64% since the previous quarter but it is down by 22% year-on-year
Forte Biosciences's debt is 100% less than its equity
The equity has contracted by 13% from the previous quarter and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.